Tevogen Bio Holdings (NASDAQ: TVGN) announced the execution of a non-binding Letter of Intent to evaluate the potential acquisition of Sciometrix Inc., a healthcare technology company specializing in digital care management solutions. Under the proposed transaction framework, Tevogen would acquire a majority voting interest in Sciometrix, positioning the combined entity to leverage the target's Clinicus platform alongside Tevogen's existing artificial intelligence initiatives.
The strategic combination is designed to establish Tevogen as a revenue-generating healthcare enterprise by merging digital care management capabilities with the company's Tevogen.AI program. The integration would combine Sciometrix's established technology platform with Tevogen's AI infrastructure, creating a comprehensive digital health solution. The Letter of Intent is non-binding and does not guarantee completion of a definitive transaction.
Tevogen Bio Holdings develops personalized immunotherapies and precision medicine solutions. The proposed acquisition represents the company's expansion into digital health technologies, a sector increasingly central to modern healthcare delivery and patient engagement strategies. Tevogen intends to conduct further evaluation and due diligence to determine whether to proceed with definitive acquisition agreements.